Projecting urinary and sexual function after first-line treatment for prostate cancer

Data from a study conducted by a research team at Fox Chase Cancer Center here in Philadelphia may be able, in time, to help to identify when and how much various prostate cancer treatments will impact urinary and sexual functioning. … READ MORE …

Is the “flare” response to initiation of LHRH therapy “real” or not?

For all of the past 30 years, it has been the accepted wisdom that starting a patient on medically induced androgen deprivation therapy (ADT, e.g., with leuproplide acetate/Lupron) during treatment of prostate cancer placed the patient at risk for an initial “flare” response that induced a short-term stimulus to serum testosterone levels and therefore to the development of any tumor. … READ MORE …

Bayer, Orion initiate Phase III trial of ODM-201 in non-metastatic CRPC

According to a media release today from Bayer HealthCare and Orion Corporation (a Finnish pharmaceutical company), they have started to  enroll patients in a randomized Phase III clinical trial of ODM-201, a novel, oral androgen receptor inhibitor in development for the treatment of men with advanced forms of prostate cancer. … READ MORE …

D’Amico on the individualization of prostate cancer risk management

In an interesting article in the September 2014 issue of The ASCO Post, Dr. Anthony D’Amico argues in favor of a future in which individualized approaches to risk will replace PSA screening alone as a means of determining who actually needs to be biopsied and (if necessary) receive treatment for clinically significant prostate cancer. … READ MORE …

Cancer screening re-visited again

An article by Melinda Beck in today’s issue of The Wall Street Journal discusses the complex topic of screening, “over-diagnosis”, and over-treatment of low-risk forms of certain cancers (prostate cancer specifically included). … READ MORE …

15-year survival and related data after first-line brachytherapy

Stone, Stock, and colleagues at the Icahn School of Medicine at Mount Sinai, New York, have been treating prostate cancer patients with brachytherapy since 1990 and (to whatever extent was possible) maintaining meticulous records throughout that time period. … READ MORE …

FDA approves use of enzalutamide in chemotherapy-naive mCRPC

This afternoon the U.S. Food & Drug Administration approved enzalutamide (Xtandi) as a treatment for patients with chemotherapy-naive, metastatic, castration-resistant prostate cancer (mCRPC) based on the results of the PREVAIL trial. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,142 other followers